Compare STG & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STG | COCH |
|---|---|---|
| Founded | 2003 | 1995 |
| Country | China | United States |
| Employees | N/A | 47 |
| Industry | Other Consumer Services | Blank Checks |
| Sector | Real Estate | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.1M | 53.4M |
| IPO Year | 2017 | N/A |
| Metric | STG | COCH |
|---|---|---|
| Price | $3.86 | $0.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 9.9K | ★ 887.7K |
| Earning Date | 05-21-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.58 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.10 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.44 | $0.36 |
| 52 Week High | $11.53 | $1.89 |
| Indicator | STG | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 52.22 | 45.50 |
| Support Level | $3.68 | $0.64 |
| Resistance Level | $4.77 | $0.75 |
| Average True Range (ATR) | 0.15 | 0.07 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 47.15 | 15.18 |
Sunlands Technology Group operates in China's adult online education market and adult personal interest learning market through its online platforms. The Group has a deep understanding of the educational needs of its prospective students and offers solutions to help them achieve their goals. It provides online professional courses and educational content, including interest, professional skills, professional certification preparation courses, and degree- or diploma-oriented post-secondary courses. The Group adopts a counseling-oriented sales and marketing approach to offer education solutions based on students' backgrounds and goals, delivering adult online education and personal interest learning through extensive course and content offerings.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.